Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Enasidenib (AG-221) is the only approved IDH2 inhibitor, clinical study found Enasidenib have some side-effects. In this work, we synthesized series of novel s-triazine derivatives, and the in vitro and in vivo activity of anti-AML has been studied using AM7577 model. The cell activity found Ta and Th showed excellent inhibition to AM7577. We further used the HuKemia Acute Leukemia xenograft model to investigate the in vivo efficacy of compounds Ta and Th, compared with AG-221, although Ta and Th can't reduce the 2-HG level obviously, those two compounds can prolong the survival of rats. The research can expand the structure of novel IDH2 inhibitors and provide useful information for further research of novel AML drugs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bioorg.2022.106225 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
MALNC: a new mutant NPM1/IDH2 and PML-RARA-associated lncRNA with impact on AML cell proliferation, maturation and drug response.
Cancer Gene Ther
August 2025
Department of Medicine, Center for Hematology and Regenerative Medicine, Karolinska Institute, Huddinge, Sweden.
As the non-coding genome remains poorly characterized in acute myeloid leukemia (AML), we aimed to identify and functionally characterize novel long non-coding RNAs (lncRNAs) relevant to AML biology and treatment. We first identified lncRNAs overexpressed in AML blasts and, among them, discovered a novel transcript, which we named myeloid and AML-associated intergenic long non-coding RNA (MALNC). MALNC is overexpressed in AML, particularly in cases with the PML-RARA fusion or IDH2/NPM1 co-mutations, and is associated with a distinct gene expression profile.
View Article and Find Full Text PDFUpdated Insights into the Molecular Pathophysiology of Olfactory Neuroblastoma Using Multi-Omics Analysis.
J Pers Med
July 2025
Department of Neurosurgery, University of Michigan, Ann Arbor, MI 48109, USA.
: Olfactory neuroblastoma (ONB), also known as esthesioneuroblastoma, is a rare neuroectodermal malignancy of the nasal cavity characterized by aggressive local invasion and variable metastatic potential, with diverse clinical behavior, often presenting at advanced stages. ONB poses challenges for targeted therapeutic strategies, despite advances in surgical and multimodal treatment strategies, because of the rarity of this disease and the limited understanding of its molecular pathophysiology. : A comprehensive review of genomic, multi-omic, and molecular studies was performed to integrate known targeted sites in ONB with the current understanding of its pathophysiology.
View Article and Find Full Text PDFUtility of IDH1/2 mutations as biomarkers for detection of measurable residual disease in acute myeloid leukemia.
Blood Adv
July 2025
Erasmus University Medical Center, Rotterdam, Netherlands.
Molecular measurable residual disease (MRD) assessment in acute myeloid leukemia (AML) patients has been established for only a few specific markers, i.e. mutant NPM1 and FLT3-ITD.
View Article and Find Full Text PDFSynthesis, characterization, DFT analysis, and molecular docking studies of carbothioamide Schiff base-phenanthroline ternary metal complexes: multi-targeted therapeutic agents against leukemia, and biomedical application.
Med Oncol
July 2025
Chemistry Department, Faculty of Science, Cairo University, Giza, 12613, Egypt.
This study reports the synthesis and biomedical evaluation of novel ternary metal complexes based on a tridentate Schiff base ligand (CHPT) and 1,10-phenanthroline (PHEN) as a co-ligand. The ligand, (Z)-2-((E)-1-(2-(4-chlorophenyl)hydrazineylidene)propan-2-ylidene)-N-phenylhydrazine-1-carbothioamide, was used to construct Fe(III), Co(II), and Cu(II) complexes. The complexes were characterized using elemental analysis, FT-IR, UV-Vis, mass spectroscopy, and conductivity measurements.
View Article and Find Full Text PDFDiscovery and structure-activity relationship study of novel hydantoin-based inhibitors targeting mutant isocitrate dehydrogenase 1 (mIDH1).
Eur J Med Chem
November 2025
School of Pharmaceutical Sciences, Chongqing Key Laboratory of Natural Product Synthesis and Drug Research, Chongqing University, Chongqing, 401331, PR China. Electronic address:
Mutations in isocitrate dehydrogenases (IDHs) are frequently observed in various malignancies. These mutations confer a neomorphic enzymatic activity, leading to the reduction of α-KG to the oncometabolite 2-HG. The aberrant accumulation of 2-HG inhibits α-KG-dependent histone and DNA demethylases, thus contributing to tumorigenesis.
View Article and Find Full Text PDF